A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

Primary Sponsor

Victorian Comprehensive Cancer Centre (VCCC)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

32

Final Accrual

32

Closing Date of Accrual

22 November 2022

Trial Chairperson

Dr Steven David, Peter MacCallum Cancer Centre, VIC

Related Post

17 November, 2026

Every kilometre counts: TROG supporters go the distance for cancer research

LATEST NEWS: 17 November 2026 From early morning walks

10 November, 2026

Golfers tee off for annual TROG fundraiser

LATEST NEWS: 10 November 2026 The Myall Coast Veteran